



## Developing Breakthrough PCR Testing for Infectious Diseases @ANYWHERE™

### CORE TEAM

Kevin Kraus, MBA  
Chief Executive Officer

Mark Kelleher, PhD  
EVP, Research & Development

Jay Foust, MBA  
EVP, Business Development

Shelle Pourmanafzadehardabili  
VP, Business Operations

Barbara Handelin, PhD  
Board Member, pioneer in PCR

Russ Hullet  
Co-Founder, Board Director

Bob Blomquist  
Co-Inventor, Board Chair

### KEY ADVISORS

Chuck Henry, PhD  
Professor Chemical & Biological  
Engineering, CSU

Mickey Urdea, PhD  
Diagnostics Advisor & pioneer

### INTELLECTUAL PROPERTY

- Landmark US Patent #12,344,889 issued July 2025
- Exclusive rights to IP co-developed with University of Colorado Anschutz
- 5 patents pending

### ASK

**\$6M (1<sup>st</sup> tranche of \$2.75M)**

- Expand evidence and utility
- Quality & regulatory systems
- Patent prosecution
- Manufacturing, sales, and partnering
- Handheld device development

### PROBLEM

- 14M people die from infectious diseases every year.
- People lack access to affordable, accurate, and rapid diagnostic tests needed to detect infectious diseases.
- Polymerase Chain Reaction (PCR) is the gold standard test, but it's time-consuming and costly pre-analytic steps keep it confined to centralized labs.

### OUR SOLUTIONS

- Affordable, reliable, and faster infectious disease testing.
- Direct-to-PCR technologies that eliminate DNA/RNA purification with novel, non-toxic chemistry.



Simplify conventional PCR



Outside the lab: PCR, instrument-free @ANYWHERE™

### CLINICALLY VALIDATED

- >590,000 direct-to-PCR patient tests (SARS-CoV-2, Influenza) performed in a CLIA-certified lab in Colorado.
- Testing enabled by our IP generated \$14M in revenue.
- 5-10x faster, lower cost and same high accuracy compared to conventional PCR.
- Planning external validation studies for respiratory and sexually transmitted infection (STI) assays through strategic collaborations and non-dilutive grants.

### TARGET MARKET OPPORTUNITY

- ~\$20B global molecular diagnostics market (labs and manufacturers), spanning reagents, sample collection, and centralized and point-of-care PCR; \$12B initial target.
- Drive DirectAmp™ reagent sales (RUO initially, then IVD post-510(k) clearance).
- Establish channel distribution, OEM integration, and licensing partnerships.

### IMPACT

- Enable simpler PCR for infectious diseases @ANYWHERE™.
- Sustainable growth and >30% fewer deaths annually.